Dr. Shinabarger has 16 years of antimicrobial discovery and development experience with Procter & Gamble Pharmaceuticals, Pharmacia Corporation and Micromyx. While at Pharmacia, Dr. Shinabarger was responsible for elucidating the mechanism of action and resistance of the antibiotic Zyvox™, the first totally new antibiotic class approved in over 30 years. He was chosen to be a member of the Zyvox™ Development Team that presented this important new antibiotic to the FDA advisory committee in April 2000 and worked extensively with the Pharmacia marketing group to introduce Zyvox™ to physicians around the world. Dr. Shinabarger served as the team leader for discovering new antibiotics, managing a multidisciplinary team of 40 scientists. He also identified, contracted, and managed three important collaborations with academic researchers, and served on several teams that sought CROs for genomics and high-throughput screening projects. Dr. Shinabarger served as a member of the Pharmacia Research Leadership Team, contributing to the review and selection of compounds for drug development. In recognition of his scientific and leadership accomplishments, he was appointed to the Pharmacia Fellows Program in April 2000 and received a Special Recognition Award in 2003 for an important discovery in antibiotic research. At Micromyx, Dr. Shinabarger functions as Chief Executive Officer and continues to be actively engaged in antimicrobial research. Dr. Shinabarger has been invited to speak at several international meetings and is an author on 26 peer reviewed publications.

return to top

Gary Zurenko has over 30 years experience in antimicrobial research at The Upjohn Company, Pharmacia and Micromyx. While at Upjohn/Pharmacia, he was a principal scientific contributor to the successful introduction of the following antimicrobial agents: Cleocin T™ (acne), Cleocin Vaginal Cream™ (bacterial vaginosis), Zefazone™ (surgical prophylaxis), Vantin™ (respiratory infections), and Zyvox™ (life-threatening Gram-positive infections). A notable accomplishment was being one of three founding scientists for the Upjohn oxazolidinone program, which ultimately led to the discovery, development, and regulatory approval of Zyvox™. Mr. Zurenko directed or contracted all of the microbiological studies required to gain FDA approval of the drug. During the Zyvox™ development process, Mr. Zurenko also served as the Regulatory Filing Team Representative for Pharmacia Discovery Research. In that capacity he was responsible for the preparation of the Microbiology section of the NDA (5000 pages) and EU Dossier, presentation of the microbiology data in all global regulatory agency venues (including the FDA Advisory Hearing), and negotiating the Microbiology portion of the Zyvox™ package insert. At Micromyx, Mr Zurenko functions as Chief Scientific Officer providing direction for client projects as well as other consulting services.

return to top